Delving into the Latest Updates on 苏州颐华生物医药技术有限公司 with Synapse

概览

关联

1

项与苏州颐华生物医药技术有限公司相关的药物

Anyu Peibo Capsule

安郁沛勃胶囊

靶点-

作用机制-

在研机构-

原研机构

上海市精神卫生中心（上海市心理咨询培训中心）

在研适应症-

非在研适应症

抑郁症 [+2]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

4

项与苏州颐华生物医药技术有限公司相关的临床试验

CTR20191740 / Active, not recruiting临床3期

随机、双盲、多中心、安慰剂平行对照，评价安郁沛勃胶囊治疗抑郁症的有效性和安全性的Ⅲ期临床试验

以安慰剂为对照，评价安郁沛勃胶囊治疗抑郁症的有效性和安全性

开始日期2020-01-19

申办/合作机构

苏州颐华生物医药技术有限公司

[+1]

CTR20170534 / Completed临床2期

分层随机、双盲、多中心、安慰剂平行对照，评价安郁沛勃胶囊治疗抑郁症的安全性和有效性的Ⅱb期临床试验

以安慰剂为对照，评价安郁沛勃胶囊治疗抑郁症的安全性和有效性，为Ⅲ期临床试验方案制定提供科学依据。

开始日期2017-06-30

申办/合作机构

苏州颐华生物医药技术有限公司

[+1]

CTR20150184 / Completed临床2期

评价安郁沛勃胶囊治疗抑郁症的安全性和有效性的随机、双盲、安慰剂平行对照、剂量探索的多中心临床试验

评价不同剂量的安郁沛勃胶囊治疗抑郁症的安全性和有效性；初步评价剂量和效应的关系，为Ⅱb期临床试验给药方案（包括给药剂量和给药周期）的确定提供科学依据。

开始日期2015-03-25

申办/合作机构

苏州颐华生物医药技术有限公司

[+1]

100 项与苏州颐华生物医药技术有限公司相关的临床结果

登录后查看更多信息

0 项与苏州颐华生物医药技术有限公司相关的专利（医药）

登录后查看更多信息

2

项与苏州颐华生物医药技术有限公司相关的文献（医药）

2020-07-01·Carbohydrate Polymers1区 · 化学

Structure characterization of a heavily fucosylated chondroitin sulfate from sea cucumber (H. leucospilota) with bottom-up strategies

1区 · 化学

Article

作者: Jiang, Yi ; Yao, Yiming ; Qiu, Piaopiao ; Chen, Lei ; Ouyang, Yilan ; Jin, Yongsheng ; Yi, Lin ; Ding, Xiujuan ; Zhang, Zhenqing ; Wu, Fangxia

Two bottom-up strategies, disaccharide and oligosaccharide analyses, were applied to elucidate the structure of a fucosylated chondroitin sulfate (FCS). The FCS was hydrolyzed with mild acid. The remained part was digested with CS lyase for disaccharide analysis. The products from each step were analyzed and the results revealed that mild sulfuric acid mainly released sulfated fucose branches, but also affected some residues and sulfo-groups on the backbone. Over 140 oligosaccharide fragments were generated by catalytic oxidation and identified by HPSEC-MS, including sulfated fucose oligosaccharides exclusively from branches, sulfated backbone fragments, and junctional fragments. Based on the results provided by these two methods, the proposed backbone of the FCS is mainly composed of GlcA→GalNAc4S6S and GlcA→GalNAc6S, and the branch is mainly located at GalNAc. The longest branch observed is nonasaccharide, and most of the fucose on the branches are mono and/or di-sulfated. NMR results supported the conclusion.

Experimental and Therapeutic Medicine4区 · 医学

Protective role of phenylethanoid glycosides, Torenoside�B and Savatiside A, in Alzheimer's disease

4区 · 医学

Article

作者: Fan, Jing ; Kang, Naixin ; Zhao, Xingxing ; Liu, Yanli ; Li, Shanshan ; Peng, Panpan ; Cao, Keke ; Zhu, Yingying ; Xu, Qiongming ; Yang, Shilin ; Ji, Shiliang

The current study assessed the efficacy of two phenylethanoid glycosides (PhGs), Torenoside B (TB) and Savatiside A (SA), in the treatment of Alzheimer's disease (AD). The effects of TB and SA compounds were first assessed following amyloid beta (Aβ)_25-35 induction in SH-SY5Y cells at a range of concentrations. Their effects on cell viability and reactive oxygen species (ROS) were determined by performing MTT and dichlorofluorescin diacetate assays, respectively. The concentration of intracellular Ca²⁺ was determined using Fluo-3AM to stain SH-SY5Y cells. SA and TB treatments were also assessed in Aβ_25-35-induced mice. Y-maze and Morris water maze methods were utilized to assess murine learning and memory capability. The pathological changes of murine hippocampi was determined using H&E and Nissl staining. In addition, biochemical parameters associated with intracellular reactive oxygen pathways including Maleic dialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), acetylcholinesterase (AChE) and Calnexin were also assessed. TB and SA treatment in Aβ_25-35-induced SH-SY5Y cells resulted in the restoration of cell morphology, an increase of SOD and GSH-Px activity, a decrease in ROS, Ca²⁺ and MDA content, and a decrease in Calnexin expression. Furthermore, SA or TB treatment administered to Aβ_25-35-induced mice improved their spatial/non-spatial learning and memory capabilities. The efficacy of treatment was also supported by a marked change in the morphological structure of pyramidal neurons in the CA1 areas of murine hippocampi, as well as an increase of SOD and GSH-Px activity. Treatment also resulted in a decrease in MDA content, AchE activity and Calnexin expression in murine hippocampal tissue. As potential AD treatment drugs, SA and TB compounds have been demonstrated to alleviate the oxidative stress induced by Aβ_25-35 via the regulation of intracellular calcium homeostasis and Calnexin, preventing AD development.

1

项与苏州颐华生物医药技术有限公司相关的新闻（医药）

2022-09-20

·国家药品监督管理局政务服务门户

2022年09月20日药品通知件待领取信息发布

序号受理号药品名称申请人签发日期1CXZB2200004国安郁沛勃胶囊苏州颐华生物医药技术股份有限公司2022年09月16日2CYHB2150675国阿司匹林肠溶片桂林南药股份有限公司2022年09月16日3CYHB2150748国阿司匹林肠溶片乐普恒久远药业有限公司2022年09月16日4CYHB2151075国依托泊苷注射液齐鲁制药（海南）有限公司2022年09月16日5CYHB2201082国布洛芬混悬液上海强生制药有限公司2022年09月16日6CYHS1401431唑来膦酸注射液石药集团欧意药业有限公司2022年09月16日7CYHS2000897国注射用阿扎胞苷健进制药有限公司2022年09月16日8CYHS2101904国赖氨洛芬注射液四川维奥制药有限公司2022年09月16日9CYHS2200572国盐酸鲁拉西酮片丽珠集团丽珠制药厂2022年09月16日10CYZB2101713国蒺藜皂苷胶囊长白山制药股份有限公司2022年09月16日11CYZB2101714国蒺藜皂苷提取物长白山制药股份有限公司2022年09月16日12CYZB2101835国牛黄上清丸河南省广康药业有限公司2022年09月16日13JYHB2240001国玻璃酸钠注射液明治制果药业株式会社；广东明治医药有限公司2022年09月15日

100 项与苏州颐华生物医药技术有限公司相关的药物交易

登录后查看更多信息

100 项与苏州颐华生物医药技术有限公司相关的转化医学

登录后查看更多信息